Obermatt

Zealand Pharma

CPH:ZEAL · DK0060257814
BiotechnologySmall

360

78
EV / EBIT93
Price / Owner Earnings21
Owner Earnings Yield100
Dividend Yield1
Price/Sales41
EV / Gross Profit100
Price/Book50
Return on Capital99
Cash Return on Capital98
Return on Equity98
EBIT Margin100
Gross Profitability90
Cash Conversion51
Accruals24
Owner Earnings Margin98
Sales growth13
Profit Growth90
Long-Term EPS Growth1
Reinvestment17
Price momentum13
Debt load73
Refinancing56
Debt Payback100
Liquidity95
Analyst ratings17
Opinion Changes50
Price Target Upside62
Market mood100
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Zealand Pharma clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryDenmark
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeCPSE
Founded1997
Employees566
ISINDK0060257814
Last UpdateApr 2, 2026
Themes
ObesityGastroenterologyBiopharmaBiotechnologyHealth Care

Description

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines. Business Segments The company operates in multiple business segments which include research and development, colla…

Analysis

Hidden champion

Zealand Pharma A/S is what we call a hidden champion: a strong business that the market is not pricing as one. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is attractive. You pay 3.2× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -20% yearly growth; analysts expect -90%. The market is pricing in far more than analysts expect: heroic expectations.

The trajectory is tepid and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
40
2026

All-time high

40

Jun 2026

All-time low

17

Mar 2026

Average rank

29

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
41
Price/Earnings
9
Price/Book
50
Dividend Yield
1
Value (overall)
9

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Zealand Pharma with its peers
Kuros Biosciences
SWX:KURN
80
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Mereo BioPharma Group
NAQ:MREO
51
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Immunovant
NSQ:IMVT
86
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Galapagos
AEX:GLPG
76
CountryBelgium
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Adocia
PAR:ADOC
63
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
ProQR Therapeutics
NAQ:PRQR
19
CountryNetherlands
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →